Figure 2From: Post-treatment neutrophil-to-lymphocyte ratio in predicting prognosis in patients with metastatic clear cell renal cell carcinoma receiving sunitinib as first line therapyCancer-specific survival of the patients stratified by the pre-treatment and post-treatment NLR. (1) By the cut-off point 2.5 of pre-treatment NLR. (2) By the cut-off point 1.1 of post-treatment NLR.Back to article page